# Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.

> **NCT00758628** · PHASE4 · COMPLETED · sponsor: **Bp Consulting, Inc** · enrollment: 50 (estimated)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Bromefenac
- **DRUG:** Blink

## Key facts

- **NCT ID:** NCT00758628
- **Lead sponsor:** Bp Consulting, Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2009-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00758628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00758628, "Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00758628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*